This single-arm, open-label, multicenter study will evaluate the safety and tolerability and the efficacy in reducing disease activity of tocilizumab [RoActemra/Actemra] as monotherapy or in combination with methotrexate in patients with active moderate to severe rheumatoid arthritis (RA). Patients are eligible to participate in this study if they are currently experiencing an inadequate response to a stable dose of a non-biologic DMARD. Patients will receive 8 mg/kg tocilizumab [RoActemra/Actemra] as an intravenous infusion every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 24 weeks. The target sample size is 50-200 patients.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01063062?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
